Phase II Trial: Erlotinib EGFR Inhibitor in Triple Oral Regimen

This Phase II study sponsored by Mayo Clinic evaluates the safety, feasibility, and potential efficacy of a triple oral chemotherapy regimen (methotrexate, erlotinib, celecoxib) in rural Midwest patients with recurrent or metastatic oral cavity cancer, using 28-day treatment cycles and scheduled imaging for response monitoring.